Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics, Inc. registers the resale of up to 2,678,570 shares of its common stock pursuant to a shelf prospectus to satisfy a contractual registration covenant.
The registration consists of 1,116,070 Purchased Shares issued at $4.48 per share and up to 1,562,500 Conversion Shares issuable upon conversion of notes (conversion price $6.72). The Company will not receive proceeds from resales. Shares outstanding were 82,565,835 as of May 31, 2026.
Opus Genetics, Inc. reported on its expanding pipeline of gene therapies for inherited retinal diseases after hosting a Research and Development Science Forum. The company highlighted five IRD programs, with four clinical data readouts expected in 2027, and said RDH12, MERTK and RHO programs are expected to enter clinical testing over the next 12 to 18 months.
Management stated that its cash runway extends into 2029 and is expected to fund multiple clinical inflection points and potential product approvals, as well as opportunities for Priority Review Vouchers. Opus Genetics’ pipeline includes seven AAV-based programs, led by OPGx-LCA5 and OPGx-BEST1, targeting severe inherited retinal disorders.
Opus Genetics, Inc. furnishes an investor presentation from its Virtual R&D Science Forum, outlining its inherited retinal disease (IRD) gene therapy strategy and pipeline. The company highlights seven AAV-based programs targeting LCA5, BEST1, RDH12, MERTK, RHO, NMNAT1 and CNGB1, with worldwide rights to all programs.
Management states Opus is fully funded into 2029 to advance five IRD clinical programs through potential product approvals and Priority Review Voucher opportunities. Key near-term milestones include a PDUFA date in October 2026 for a partnered phentolamine sNDA, BEST1 Cohort 1 three‑month results in September 2026, Phase 3 dosing for LCA5 in Q4 2026, and initial RDH12 and MERTK clinical study initiations between Q4 2026 and Q1 2027. Four clinical data readouts are expected in 2027.
The presentation details disease biology, prevalence and preclinical data for RDH12, MERTK, RHO, LCA5 and BEST1, along with patient‑reported outcomes from the OPGx‑LCA5 study showing maintained or improved visual acuity and functional vision gains in small adult and pediatric cohorts. Opus also emphasizes global IRD prevalence, strategic partnerships for trial recruitment, and a dose‑exploration, data‑driven clinical development approach.
Opus Genetics, Inc. registers up to 2,678,570 shares of Common Stock for resale by selling stockholders.
The shares consist of 1,116,070 Purchased Shares issued under a Stock Purchase and Conversion Agreement and up to 1,562,500 Conversion Shares issuable upon conversion of Notes under a Note Purchase Agreement, with a Conversion Price of $6.72 per share. The company will not receive proceeds from resales; the registration satisfies a contractual covenant and permits the selling stockholders to sell on market or by private transactions. Shares outstanding were 82,565,835 as of May 31, 2026; last reported sale price was $4.12 on June 1, 2026.
Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. filed Amendment No. 3 to their Schedule 13D for Opus Genetics, Inc. The filing reflects a reduced position of 3,792,171 shares of common stock, representing 4.66% of the company’s outstanding shares.
This change results from selling Opus Genetics common stock on May 18, 2026. Based on 81,395,539 shares outstanding as of May 7, 2026, the reporting persons now hold less than five percent and characterize this amendment as an exit filing ending their Schedule 13D reporting obligations.
Opus Genetics, Inc. director entities Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. reported an open-market sale of 1,700,000 shares of Common Stock of Opus Genetics at $4.35 per share.
The shares are owned directly by Foundation Fighting Blindness Retinal Degeneration Fund, whose board controls voting and investment decisions, while Foundation Fighting Blindness, Inc. is its sole member and may be deemed to beneficially own these securities. After the transaction, the reporting entities continue to hold 3,792,171 shares of Opus Genetics common stock.
Opus Genetics, Inc. ownership disclosure: Nantahala Capital Management, LLC and related reporting persons report beneficial ownership of 4,839,225 shares of Common Stock as of March 31, 2026. The filing states that 3,157,895 of those shares may be acquired within sixty days through the exercise of convertible securities. Each of Nantahala, Wilmot B. Harkey and Daniel Mack is reported as beneficially owning 6.51% of the outstanding shares, with shared voting and dispositive power over the 4,839,225 shares.
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund filed Amendment No. 2 to a Schedule 13G/A reporting 9.99% beneficial ownership of Opus Genetics, Inc. common stock.
The filing states the ownership percentages are calculated using 81,395,539 shares outstanding as of May 7, 2026 and assume exercise of Warrants that the Reporting Persons hold. The Master Fund directly holds 1,835,842 shares, Pre-Funded Warrants exercisable for 13,617,584 shares and Common Warrants exercisable for 13,157,895, subject to the "Beneficial Ownership Limitation." The limitation permits exercise for up to 6,994,303 shares under current conditions. Shared voting and dispositive power are reported as 8,830,145 shares for each Reporting Person.
Opus Genetics, Inc. ownership disclosure: Caligan Partners LP and David Johnson report beneficial ownership of 6,075,028 shares of common stock, representing 8.5% of the class. The percentage is calculated using 71,402,472 shares outstanding as of 03/31/2026, per cited filings.
The Schedule 13G names Caligan as the investment manager to certain funds and Mr. Johnson as Managing Partner; both signed the filing on 05/15/2026.